Numerous tumor‐specific genetic alterations such as typical isocitrate dehydrogenase (IDH) mutation and chromosome 1p/19q codeletion were routinely applied in diagnosis according to the 2021 World Health Organization (WHO) classification system, but whether these gene aberrations affect glioma progression remains debatable.3, 4. The gene discussed is IDH1; the disease is glioma.